1. Home
  2. NUVL vs RH Comparison

NUVL vs RH Comparison

Compare NUVL & RH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$100.40

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo RH

RH

RH

HOLD

Current Price

$193.25

Market Cap

3.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
RH
Founded
2017
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Specialty Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
3.2B
IPO Year
2021
1998

Fundamental Metrics

Financial Performance
Metric
NUVL
RH
Price
$100.40
$193.25
Analyst Decision
Strong Buy
Hold
Analyst Count
15
16
Target Price
$135.00
$227.33
AVG Volume (30 Days)
483.4K
1.2M
Earning Date
10-30-2025
12-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.11
EPS
N/A
5.52
Revenue
N/A
$3,409,319,000.00
Revenue This Year
N/A
$12.43
Revenue Next Year
N/A
$8.89
P/E Ratio
N/A
$35.02
Revenue Growth
N/A
9.74
52 Week Low
$55.54
$123.03
52 Week High
$112.88
$455.84

Technical Indicators

Market Signals
Indicator
NUVL
RH
Relative Strength Index (RSI) 43.70 70.03
Support Level $99.38 $178.61
Resistance Level $106.65 $189.68
Average True Range (ATR) 2.84 8.17
MACD -0.80 2.29
Stochastic Oscillator 14.80 91.23

Price Performance

Historical Comparison
NUVL
RH

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About RH RH

RH is a luxury furniture and lifestyle retailer operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories including furniture, lighting, textiles, bath, decor, and children and is growing the presence of its hospitality business with 23 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.

Share on Social Networks: